我的購物車 (0)
我的帳號資料
我的訂單紀錄
我的學校教授
我的學校課程

[ Tips ] 一分鐘使用導覽

搜尋 
請輸入欲查詢之關鍵字
 
  進階搜尋
依主題瀏覽 
依商品類型瀏覽 
依出版日期瀏覽 
依作者瀏覽(姓) 
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
V
W
Y
Z
銷售排行榜 
 您所選取的商品項目

> Intermountain Healthcare: Pursuing Precision Medicine

商品編號: 9-818-018
出版日期: 2017/09/28
作者姓名:
Hamermesh, Richard G.;Giusti, Kathy;Huckman, Robert S.;Kelley, Julia
商品類別: Entrepreneurship
商品規格: 22p

再版日期: 2023/02/08
地域: Utah
產業: Healthcare service industry;Insurance industry
個案年度: 2013 -  2017

 


商品敘述:

Headquartered in Salt Lake City, Intermountain Healthcare operates 23 hospitals and hundreds of clinics in Utah and Idaho and provides insurance to approximately 850,000 patients through its insurance arm, SelectHealth. In 2013, Intermountain, known for its commitment to improving health care outcomes and lowering costs by reducing treatment variation, made the surprising decision to invest significant resources in an innovative precision medicine unit, which would provide life-extending, genetically-targeted therapies to late-stage cancer patients. Precision medicine was associated with treatment variation and high costs, the latter of which was of particular concern given that Intermountain often served as both payer and provider for its patients. But Intermountain''s management was convinced by Lincoln Nadauld, MD, PhD, who joined Intermountain''s oncology team in 2013 and spearheaded the creation of Intermountain Precision Genomics (IPG). By 2016, IPG had a cutting-edge genomic sequencing laboratory that provided sequencing services to Intermountain and non-Intermountain physicians, and IPG''s team had conducted research indicating that targeted therapies administered through IPG extended patient lifespans but increased overall costs. Now, in mid-2017, IPG is undergoing a major transition as it prepares to outsource the bulk of its genomic testing volume to Navican Genomics, a for-profit, Intermountain-owned spinoff. As Nadauld contemplates the future of IPG, he must evaluate two exciting opportunities, and students are asked to consider where Nadauld should focus IPG''s resources: should IPG partner with Intermountain''s behavioral health team to conduct joint research on the relationship between genetic markers and antidepressant effectiveness, or should IPG push for the testing of a large biorepository, which will cost $12 million but could lead to the identification of new precision medicine applications? More broadly, students will also need consider the ways in which IPG complements or conflicts with Intermountain''s mission and culture.


涵蓋領域:

Corporate social responsibility;Decision making;Disruptive innovation;Entrepreneurship;Health care and treatment;Leadership;Service management;Technology and analytics


相關資料:

, (9-820-019), 11p, by Richard G. Hamermesh, Robert S. Huckman, Julia Kelley